اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,932
تعداد مقالات33,084
تعداد مشاهده مقاله43,732,422
تعداد دریافت فایل اصل مقاله20,244,027
Muayad Shukur Al Obaidi, R. (1400). The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy. سامانه مدیریت نشریات علمی, 76(3), 639-647. doi: 10.22092/ari.2021.355463.1688
R Muayad Shukur Al Obaidi. "The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy". سامانه مدیریت نشریات علمی, 76, 3, 1400, 639-647. doi: 10.22092/ari.2021.355463.1688
Muayad Shukur Al Obaidi, R. (1400). 'The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy', سامانه مدیریت نشریات علمی, 76(3), pp. 639-647. doi: 10.22092/ari.2021.355463.1688
Muayad Shukur Al Obaidi, R. The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy. سامانه مدیریت نشریات علمی, 1400; 76(3): 639-647. doi: 10.22092/ari.2021.355463.1688

The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy

Archives of Razi Institute
مقاله 26، دوره 76، شماره 3، آذر 2021، صفحه 639-647    اصل مقاله (421.76 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.355463.1688
نویسنده
R Muayad Shukur Al Obaidi*
College of Medical and Health Technologies, Ahlulbyt University, Karbala, Iraq
چکیده
Obesity triggers the development of adipokines such as leptin, resistin, and visfatin, which have been associated with the development of diabetic nephropathy and other vascular disorders. The main purpose of the current investigation was to identify the physiological impact of visfatin on immunological response and its inflammatory effects on nephropathy. Fifty Iraqi patients with chronic kidney disease (CKD) at various stages, as described by the National Kidney Foundation (NKF) and ranging in age from 48.367.56 to 53.68 8.46 years on average were considered. Prior to the start of the investigation, informed consent was obtained from all participants, and the ethics committee approved the study. Patients were classified into two groups: Group (A) comprised patients with a GFR higher than 60 mL/minute, and Group (B) comprised patients with a GFR of less than 60 mL/min. There was no considerable variance between the groups as regards visfatin, but a highly significant correlation between serum visfatin and CRP was observed. The results of the current investigation indicated that serum visfatin levels are significantly correlated with CRP in CKD patients; it is also correlated with deterioration of kidney function. Moreover, higher visfatin levels were accompanied by increased serum triglyceride and cholesterol levels. These findings would suggest that visfatin may perform an essential function in uremia-related inflammation and may serve as a potential target for treatment and prevention of renal associated complications. Future studies may delineate whether visfatin is a marker of disease activity and severity as well as a predictor of outcome in CKD.
کلیدواژه‌ها
nephropathy؛ obesity؛ visfatin؛ adipokines؛ immune response
مراجع
  1. Hasegawa K. Novel tubular-glomerular interplay in diabetic kidney disease mediated by sirtuin 1, nicotinamide mononucleotide, and nicotinamide adenine dinucleotide Oshima Award Address 2017. Clin Exp Nephrol. 2019;23(8):987-94.
  2. Hognogi LD, Simiti LV. The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome. Clujul Med. 2016;89(3):322-6.
  3. Kang YS, Lee MH, Song HK, Kim JE, Ghee JY, Cha JJ, et al. Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice. Kidney Blood Press Res. 2016;41(3):311-24.
  4. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomed Pharmacother. 2018;107:306-28.
  5. Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38-50.
  6. Dalamaga M, Christodoulatos GS, Mantzoros CS. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges. Metab. 2018;82:72-87.
  7. Ratajczak J, Joffraud M, Trammell SA, Ras R, Canela N, Boutant M, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:13103.
  8. Landecho MF, Tuero C, Valenti V, Bilbao I, de la Higuera M, Fruhbeck G. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk. Nutrients. 2019;11(11).
  9. Marouga A, Dalamaga M, Kastania AN, Kroupis C, Lagiou M, Saounatsou K, et al. Circulating resistin is a significant predictor of mortality independently from cardiovascular comorbidities in elderly, non-diabetic subjects with chronic kidney disease. Biomark. 2016;21(1):73-9.
  10. Ren J, Wu NN, Wang S, Sowers JR, Zhang Y. Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications. Physiol Rev. 2021;101(4):1745-807.
  11. Kaminski TW, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol. 2017;18(1):35.
  12. Sakin A, Sahin S, Behlul A, Sumnu A, Gursu M, Sakin A, et al. The association of Visfatin levels with metabolic parameters and inflammation in diabetic nephropathy. East J Med. 2020;25(2):218-24.
  13. Mohammed RA, Ebrahem EE, Youssef E, Bayoumy ESJA. Serum visfatin as a biomarker of inflammation in patients with chronic kidney disease.AAMJ. 2012;10(3):2.
  14. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and
    endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2008;23(3):959-65.
  15. Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317-36.
  1. Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, Bozentowicz-Wikarek M, Brzozowska A, Mossakowska M, et al. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects. Clin Chem Lab Med. 2015;53(5):793-9.
  2. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29(1):31-5.
آمار
تعداد مشاهده مقاله: 1,388
تعداد دریافت فایل اصل مقاله: 537


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب